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Abstract
Background: Invasive mediastinal nodal staging is recommended by guidelines in selected patients with resectable
non-small cell lung cancer (NSCLC). Endosonography is recommended as initial staging technique, followed by
confirmatory mediastinoscopy in case of negative N2 or N3 cytology after endosonography. Confirmatory
mediastinoscopy however is under debate owing its limited additional diagnostic value, its associated morbidity
and its delay in the start of lung cancer treatment. The MEDIASTrial examines whether confirmatory
mediastinoscopy can be safely omitted after negative endosonography in mediastinal nodal staging of NSCLC. The
present work is the proposed statistical analysis plan of the clinical consequences of omitting mediastinoscopy,
which is submitted before closure of the MEDIASTrial and before knowledge of any results was done to enhance
transparency of scientific behaviour.
Methods: The primary outcome measure of this non-inferiority trial will be unforeseen N2 disease resulting from
lobe-specific mediastinal lymph node dissection. For non-inferiority, the upper limit of the 95% confidence interval
of the unforeseen N2 rate in the group without mediastinoscopy should not exceed 14.3% in order to probably
have no negative impact on survival. Since this is a non-inferiority trial, both an intention to treat (ITT) and a per
protocol (PP) analyses will be done. The ITT and the PP analyses should both indicate non-inferiority before the
diagnostic strategy omitting mediastinoscopy will be interpreted as non-inferior to the strategy with
mediastinoscopy. Secondary outcome measures include 30-day major morbidity and mortality, the total number of
days of hospital care, overall and disease free 2-year survival, generic and disease-specific health related quality of
life and cost-effectiveness and cost-utility of staging strategies with and without mediastinoscopy.
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Discussion: The MEDIASTrial will determine if confirmatory mediastinoscopy can be omitted after tumour negative
systematic endosonography in invasive mediastinal staging of patients with resectable NSCLC.
Trial registration: Netherlands Trial Register NL6344/NTR6528. Registered on 2017 July 06
Keywords: Non-small cell lung carcinoma, Mediastinal nodal staging, Endosonography, Mediastinoscopy, Thoracic
surgery, Statistical analysis plan
Background
Mediastinal nodal staging of non-small cell lung cancer
(NSCLC) is important to determine treatment and prog-
nosis. The European guidelines recommend invasive sta-
ging in patients with suspicious hilar or mediastinal
lymph nodes on imaging (cN1-3) or centrally located,
FDG-non-avid or large (> 3 cm) peripherally located
tumours [1, 2]. Endosonography is recommended over
surgical staging as initial staging technique. In case of
tumour negative endosonography findings (no malignant
N2 or N3 cytology) confirmatory mediastinoscopy is rec-
ommended in patients with cN1-3 and should be con-
sidered in patients with centrally located, FDG-non-avid
or peripheral tumours > 3 cm to rule out false negative
endosonography [1]. The use of confirmatory mediasti-
noscopy however is under debate owing its limited add-
itional diagnostic value (number needed to test of 11),
its associated complications (6.0%) or mortality and its
delay in the start of definite treatment [3, 4]. The MEDI
ASTrial examines whether mediastinoscopy can be safely
omitted after negative endosonography in invasive medi-
astinal nodal staging of NSCLC, based on non-inferiority
[5]. The present work is the proposed statistical analysis
plan (SAP) of the clinical consequences of omitting me-
diastinoscopy, which will be published before closure of
the MEDIASTrial and before outcome measure data
were available.
Summary study protocol
The MEDIASTrial (MEDIASTinal staging of non-small
cell lung cancer by endobronchial and endoscopic
ultrasonography with or without additional surgical me-
diastinoscopy) is a multicentre randomised, parallel-arm,
non-inferiority study in 342 patients with proven or
suspected NSCLC. The complete study protocol was
already published open access [5]. The hypothesis was
‘Omitting mediastinoscopy after negative endosonogra-
phy in mediastinal staging of NSCLC does not result in
an unacceptable percentage of unforeseen N2 disease at
surgical resection (pN2). In addition, omitting mediasti-
noscopy will shorten time until definitive surgery, will
prevent one general anaesthesia and hospital admission
and will be associated with lower morbidity and compar-
able survival. Therefore, this strategy may increase qual-
ity of life and reduce health care costs.’
Patients with proven or suspected, resectable (judged
by the thoracic surgeon on available imaging) NSCLC
without distant metastases and with an indication for in-
vasive mediastinal staging (i.e. cN1-3 or centrally lo-
cated, FDG-non-avid or large (> 3 cm) peripherally
located tumour) were eligible for inclusion. Prior to in-
clusion systematic endosonography with tissue sampling
was performed (if indicated), resulting in tumour nega-
tive findings (no malignant N2 or N3 lymph nodes).
Patients with suspected metastases to lymph node sta-
tions 5 and 6 (i.e. aortopulmonary window) on imaging
were eligible for inclusion. If metastatic spread to these
nodal stations would lead to changes in treatment strat-
egy according to the local multidisciplinary board ex-
tended invasive staging (i.e. parasternal mediastinotomy/
scopy or VATS) should have been performed. In patients
randomised in the group with mediastinoscopy, the
regular cervical mediastinoscopy should have been ex-
panded to investigate lymph node stations 5 and 6. Pa-
tients randomised in the group without confirmatory
mediastinoscopy additional staging of stations 5 and 6
should have been done in a separate session or by using
intra-operative frozen section analysis prior to the ana-
tomic lung resection. If metastatic spread to station 5 or
6 would not influence treatment, patients were treated
as described by the study protocol with or without con-
firmatory mediastinoscopy depending on randomisation
outcome.
Exclusion criteria were ‘bulky N2-N3 disease’ on FDG-
PET/CT, the combination of highly suspicious as well as
irresectable mediastinal lymph nodes, non-correctable
coagulopathy or insufficient comprehension of the
Dutch language.
After inclusion, patients were 1:1 randomised to
undergo either mediastinal staging with or without
confirmatory mediastinoscopy. Randomisation was
stratified by type of centre (Dutch academic, Dutch non-
academic, Belgian academic) and by age up to or above
66 years. Patients assigned to staging with confirmatory
mediastinoscopy received usual care conform existing
guidelines. When histopathology after mediastinoscopy
did not demonstrate N2 or N3 lymph node metastases,
patients were recommended to undergo an anatomic re-
section of the primary tumour including lobe-specific
lymph node dissection. Patients in the intervention-arm
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of the MEDIASTrial underwent immediate anatomic re-
section of the primary tumour including lobe-specific
lymph node dissection without confirmatory
mediastinoscopy.
The primary outcome measure for non-inferiority is
the proportion unforeseen N2 disease, which is defined
as pathologically proven N2 disease resulting from lobe-
specific mediastinal lymph node dissection at time of
tumour resection when previous invasive mediastinal
nodal staging showed N0 or N1 disease. The patho-
logical N stage results from the pathology report after
pathological investigation, which was standardised by
‘The nationwide network and registry of histo- and cyto-
pathology in the Netherlands’ [6]. Isolated cancer cell
and micro-metastases were classified as positive findings
when detected in lymph node dissection specimens.
Secondary endpoints include major morbidity and 30-
day mortality, the total number of days of hospital care
during 2-year follow-up, overall 2-year survival and gen-
eric and disease-specific health related quality of life.
Additionally, a cost-effectiveness and cost-utility analysis
of mediastinal staging strategies with and without medi-
astinoscopy will be done; this health economic perspec-
tive will be reported separately and falls beyond the
scope of this analysis plan for assessing the clinical
consequences.
The sample size calculation resulted in 171 patients to
include in each randomisation group, or 342 patients in
total (power 80%, alpha error 0.025). Based on an as-
sumed 5% drop-out rate of patients after randomisation,
we aim to include a total of 360 patients [5].
The medical ethical committee of Máxima Medical
Centre approved the study protocol on June 15, 2017.
The trial was registered at the Netherlands Trial
Register on July 6, 2017 (NL6344/NTR6528). MEDI
ASTrial study protocol version 7.0, approved on July
1, 2019, is the latest and currently effective study
protocol. The first patient was included on July 17,
2017, and the inclusion is expected to be complete in
2020. The full sample size calculation, study proce-
dures and further details are available in the previ-
ously published trial protocol [5].
Statistical analysis plan
The statistical analysis plan was conducted according to
the Guidelines for the Content of Statistical Analysis
Plans in Clinical Trials [7]. The checklist was provided
in Additional file 1. FvdB is the clinical chief investigator
and MD is the responsible senior statistician of the
MEDIASTrial.
General principles
The primary analyses (for evaluation of primary outcome
measure and major morbidity and 30-day mortality) will
be performed when all patients have at least 30 days
after the start of the treatment follow-up. The remaining
secondary outcome measures will be analysed after com-
pletion of 2 years follow-up of all evaluable patients. Be-
fore analysing, the database will be cleaned and locked.
No interim analysis will be performed. Analyses will be
performed using the Statistical Package for Social Sci-
ences (IBM SPSS Statistics for Windows, Armonk, NY).
Generally, numerical outcomes will be presented as
means (with standard deviation (SD) and/or range) or
medians (with interquartile range (IQR and/or range))
depending on (normally or skewed) distribution of data.
Numerical outcomes will be compared between groups
using the unpaired t test or Mann-Whitney U test de-
pending on distribution of data. Categorical data will be
presented as counts and percentages and will be com-
pared between groups using the Mantel-Haenszel chi-
squared test or using Fisher’s exact test in case of
zero cell counts [8, 9]. We will calculate 95% CI’s
around proportions by using the Wilson score interval
for proportions [10]. Correction for multiple testing
of the secondary outcome measures will be done
using the Benjamini-Hochberg method [11]. Statistical
significance will be set at a p value of less than 0.05.
In case data presentation or analysis is planned to be
different, this will be stated in the specific outcome
measure description part of this SAP. An overview of
the planned statistical test per outcome measure to
compare the randomisation groups is provided in
Additional file 2.
Patient flow diagram
As indicated in the Consolidated Standards of Reporting
Trials 2010 statement (CONSORT), the patient flow will
be illustrated in a flow diagram (Fig. 1) [12].
Intention to treat and per protocol analysis
As this is a non-inferiority trial, both intention to treat
(ITT) and per protocol (PP) analyses will be done [13].
The ITT and the PP analyses should both indicate non-
inferiority before the diagnostic strategy ‘omitting medi-
astinoscopy’ will be interpreted as non-inferior to the
strategy with mediastinoscopy. The pathology report of
the lobe-specific lymph node dissection determines the
nodal state, which is the primary outcome measure of
this study. All patients from the ITT population without
protocol deviations or violations in eligibility and study
procedures will be included in the PP analysis. All ana-
lyses of secondary outcomes will be carried out on an
ITT basis.
Protocol deviation and violation
Clinical deterioration and progression of the disease be-
tween randomisation and surgery could restrain surgical
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options and resectability of the primary tumour and
lymph nodes. Patients in whom no lobe-specific lymph
dissection was performed will be considered drop-outs
since the primary outcome measures are missing. This
population is expected not to exceed 5% as included in
the sample size calculation. Patients randomised to con-
firmatory mediastinoscopy in whom no mediastinoscopy
was performed prior to anatomical lung resection will
primarily be analysed based on intention-to-treat. In per
protocol analysis, these patients will be excluded for
analysis.
Patient replacement and missing data
A 5% drop-out rate was included in the sample size cal-
culation. As we assume the group of patients with miss-
ing primary outcome measures will not transcend this
number, no patient replacement will be performed after
inclusion of 360 patients. Clinical data management is
done by professional data managers from the Dutch
Comprehensive Cancer Centre. Any missing clinical data
will be communicated to the study site data manager for
prompt correction. Missing data in baseline characteris-
tics (including FDG-PET/CT and endosonography
Fig. 1 Enrollment, randomisation and flow of study patients. N2 = ipsilateral mediastinal lymph node metastasis; N3 = contralateral lymph node
metastasis; Unforeseen N2 disease Pathologically proven N2 disease at lobe-specific lymph node dissection at time of tumour resection when
previous mediastinal staging showed N0 or N1 disease
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results), mediastinoscopy, anatomic resection and lymph
node dissection will not be imputed. For dichotomous
variables, the actual denominator and for continuous
variables the number of patients will be stated.
Randomisation outcome and treatment results
(physical condition, complications, adjuvant therapy
and oncological/survival results) could affect the
number of completed questionnaires. Complete case
analysis will be used as primary analysis for an out-
come if the proportion of missing data is below 6%
or missing data can be handled with mixed models or
generalised estimation equations for repeated mea-
sures. In both instances, at least 342 evaluable pa-
tients should remain.
If less than 342 evaluable patients remain, missing
data patterns will be studied to assess the likelihood
of data being missing (completely) at random. Logistic
regression on missingness of data will be applied to
identify potentially associated baseline and clinical
characteristics (e.g. gender, ASA-classification, indica-
tion for mediastinal nodal staging, clinical node stage,
primary tumour location) and derive propensity scores
for having missing data [14]. Subsequently, multiple
imputation (n = 5) will be applied, including the pro-
pensity score, treatment allocation, type of centre, age
at baseline, randomisation and stratification factors.
Additionally the pathological results (pN stage), use
of adjuvant therapy and the results of previously con-
ducted questionnaires will be included. Alternatively,
single imputation by ‘last observation carried forward’
replacing missing data with the last reported value of
the same patient will be performed. Finally, a
complete case analysis of available cases (n < 342) will
be performed. Depending on the robustness of ana-
lysis results, a definitive choice for the method of
handling missing data will be made. The imputation
method with the smallest confidence interval and
point estimates closest to the results of the complete
case analysis of available cases will be considered the
most robust one. In case of a lack of robustness
because of changes in direction of the difference be-
tween treatment groups, worst and best case scenarios
of imputation will be constructed. The handling of
missing data will be extensively and transparently re-
ported in supplemental material to the final results
section.
Baseline characteristics
The following baseline characteristics will be reported
in the baseline characteristics table: age, gender, type
of centre, World Health Organization (WHO) per-
formance state, American Society of Anesthesiologists
(ASA) classification, primary tumour location (lobe),
tumour and nodal stage according to the 8th TNM
classification based on FDG-PET/CT, indication for
invasive mediastinal nodal staging and the final histo-
pathology result (Table 1). Testing for differences in
baseline characteristics among groups will only be
done if visual inspection of the results indicates pos-
sible significant differences.
Endosonography results
All included patients underwent systematic Endobron-
chial Ultrasound-guided Transbronchial Needle Aspir-
ation (EBUS-TBNA), preferably with added Endoscopic
Ultrasound-guided Fine Needle Aspiration by using the
conventional endoscope (EUS-FNA) or the EBUS endo-
scope (EUS-B-FNA). We will report the following: the
number of additional EUS procedures, sedation used,
the proportion of procedures with rapid on site evalu-
ation (ROSE), the number of visualised and sampled
lymph nodes, the number of samples per lymph node
station and the number of patients with cytologically
proven N1 disease. The outcomes will be compared
among the randomisation groups with subsequent pres-
entation of outcomes for both individual groups
(Table 2).
Cervical videomediastinoscopy results
We will report the number of visualised and sampled
lymph node stations, the proportion of lymph node
stations that were adequately sampled (i.e. at least
four surgical biopsies or one entire lymph node) and
the number of complete performed mediastinoscopy
procedures (according to the study protocol) [5].
Additionally, the pathology results whether medias-
tinal lymph node metastases were found including the
level of the affected lymph node stations will be re-
ported (Table 2). A calculation of the number needed
to test to detect a patient with missed mediastinal
lymph node metastases after endosonography by per-
forming confirmatory cervical videomediastinoscopy
will be done. Complications of mediastinoscopy will
be reported in the major morbidity and mortality out-
come measure. The patients randomised for mediasti-
noscopy who did not undergo mediastinoscopy will
be reported including the reason for this protocol de-
viation, if applicable.
Surgical reference standard
We will report the used surgical technique (video-
assisted thoracoscopic surgery (VATS) single- or multi-
port, thoracotomy), number of converted operations,
duration of surgery (minutes), used type of resection
(segmentectomy, lobectomy, bilobectomy, pneumonec-
tomy), number of sampled mediastinal lymph node sta-
tions and the number of complete lobe-specific lymph
node dissections (according to the study protocol) [5].
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The outcomes will be compared among randomisation
groups with subsequent presentation of outcomes for
both individual groups (Table 2). Complications of the
surgical lung tumour resection will be reported in the
major morbidity and mortality outcome measure. The
patients who did not undergo anatomic resection and
lobe-specific lymph node dissection will be reported
including the reason for not performing this procedure,
if applicable.
Assessment and analysis of unforeseen N2 disease
Unforeseen N2 disease is defined as pathologically
proven N2 disease resulting from lobe-specific lymph
node dissection at time of tumour resection, not
Table 1 Clinical and lung cancer characteristics of included patients
With mediastinoscopy (n=) Without mediastinoscopy (n=)





















Tumour stage FDG-PET/CT, No. (%)
T
Nodal stage FDG-PET/CT, No. (%)
N




Peripheral tumour > 3 cm





SD standard deviation, y years, No. number, WHO World Health Organization, ASA American Society of Anesthesiologists, FDG-PET fluorodeoxyglucose positron
emission tomography, CT computed tomography, TNM tumour, node, metastasis, 8th edition; NSCLC non-small cell lung cancer
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detected by invasive clinical staging including endoso-
nography nor by mediastinoscopy (if performed). Pa-
tients with suspected stations 5 and 6 metastases on
imaging who turned out to have pathologically proven
station 5 or 6 metastases resulting from lymph node
dissection will only be included in the unforeseen N2
calculation if pre-operative extended staging was per-
formed (conform study protocol). In patients with
suspect stations 5 and 6 on imaging in whom no ex-
tended staging was performed, pathological positivity
of these nodal stations will be considered foreseen N2
disease, and thus not included in unforeseen N2 cal-
culation. Patients with unsuspicious lymph nodes in
stations 5 and 6 on imaging with pathologically
proven metastases in these stations will be included
in the unforeseen N2 calculation.
As substantiated in our study protocol, the upper limit
of the two-sided 95% confidence interval (95% CI) of the
unforeseen N2 rate in the intervention group (endosono-
graphy without mediastinoscopy) should not exceed the
Table 2 Performance of diagnostic and therapeutic procedures





Rapid on-site evaluation, No. (%)
Mediastinal lymph node stations
Visualised, mean (SD)/median (IQR)
Sampled, mean (SD)/median (IQR)
Samples per station, mean (SD)/median (IQR)
Cytologically proven N1 disease, No. (%)
Confirmatory mediastinoscopy, No. (%) 0
Mediastinal lymph node stations –
Sampled, mean (SD)/median (IQR)
Adequate samplinga, % –
Proven mediastinal lymph node metastases –
N2, No (%)
N3, No. (%) –
Complete mediastinoscopyb, No. (%)
Anatomical lung resection, No. (%)
Thoracoscopic surgery, No. (%)
Conversion to thoracotomy, No. (%)






Mediastinal lymph node stations dissected, mean (SD)/median (IQR)
Complete lobe-specific lymph node dissectionb, No. (%)
Unforeseen N2, No. (%)
Foreseen N2 (station 5–6), No. (%)
EBUS endobronchial ultrasonography, EUS endoscopic ultrasonography, EUS-B endoscopic ultrasonography using the EBUS bronchoscope, No. number, SD
standard deviation, N1 ipsilateral hilar lymph node metastasis, N2 ipsilateral mediastinal lymph node metastasis, N3 contralateral lymph node metastasis
aAdequate sampling = at least 4 surgical biopsies or one entire lymph node per station
bComplete according to the study protocol [5]
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non-inferiority boundary of 14.3% in order to probably
have no negative impact on survival [15]. A formal com-
parison of the unforeseen N2 rates of the randomisation
groups with and without mediastinoscopy will be done
based on intention-to-treat and per protocol analysis.
Exploratory subgroup analysis of unforeseen N2 disease
of patients with different indications for invasive staging
(i.e. cN1-3 or centrally located, FDG-non-avid or large
(> 3 cm) peripherally located tumour) will be performed.
Finally, an overview of all patients with unforeseen N2
disease will be provided. Unforeseen N2 disease will
either be classified as detection error (lymph node
metastasis not detected by FDG-PET/CT, endosonogra-
phy nor mediastinoscopy) or sampling error (metastasis
detected by FDG-PET/CT, but missed despite lymph
node sampling during endosonography and/or
mediastinoscopy).
Major morbidity and 30-day mortality
Complications in the first 30 days after start of treat-
ment are scored using the Clavien-Dindo classification
[16]. Major morbidity is defined as Clavien-Dindo
grade III (requiring surgical, endoscopic or radio-
logical intervention) or IV (life-threatening complica-
tion requiring intensive care management)
complications or recurrent laryngeal nerve injury. Re-
current laryngeal nerve injury is considered when
postoperative hoarseness exists and should be con-
firmed by laryngoscopy, proving paralysis of a vocal
cord. The composite outcome measure will be calcu-
lated as the number of patients with major morbidity
and the number of deceased patients in the first 30
days after the start of treatment. This number divided
by the total number of randomised patients will be
considered the proportion of patients with major
morbidity or 30-day mortality per randomisation
group (Table 3).
Assessment and analysis of secondary outcomes
Patients will be followed during 2 years after start of
treatment. A minority of patients will have N2 or N3
disease diagnosed by mediastinoscopy and will therefore
possibly be judged ineligible for surgery. In these pa-
tients, the start of chemotherapy and/or radiotherapy
will be considered as start of follow-up period. Follow-
up will be done at 3, 6, 12 and 24months after start
treatment. The hereafter mentioned secondary outcome
measures will all be compared among randomisation
groups and data will be subsequently presented for the
groups.
Total number of days of hospital care
The absolute number of days of hospital care in the
period from randomisation until 2 years after start of
treatment will be registered. Every day in hospital (in-
cluding outpatient clinic visits and day care treat-
ments) related to NSCLC diagnosis, treatment or
follow-up will be included in this outcome measure.
Differences between groups will be tested with Mann-
Whitney U tests.
Overall and disease-free 2-year survival
Overall 2-year survival is defined as the proportion of
patients alive at 2 years after start of treatment. Disease-
free 2-year survival is defined as the proportion of pa-
tients alive without evidence of relapse of NSCLC at 2
years after start of treatment. The overall and disease-
free 2-year survival will be presented as Kaplan-Meier
curves and compared among the randomisation groups
using the log-rank test.
Generic and disease-specific health related quality of life
Generic health-related quality of life will be measured
using the Euroqol 5 Dimensions 5 Levels questionnaire
(EQ-5D-5L) and the European Organization for
Table 3 Morbidity and 30-day mortality
Clavien-Dindo classification grade With mediastinoscopy (n=) Without mediastinoscopy (n=)
Endosonography
Postoperative complication, No. (%)
Postoperative complication, No. (%)
Mediastinoscopy
Postoperative complication, No. (%)
Postoperative complication, No. (%)
Anatomical lung resection
Postoperative complication, No. (%)
Postoperative complication, No. (%)
30-day mortality, No. (%)
No. number. Clavien-Dindo classification: grade 1: complication without need for interventions, grade 2: complication requiring pharmacological treatment, grade
3: complication requiring surgical, endoscopic or radiological intervention, grade 4: life-threatening complication requiring intensive care management, grade
5: death
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Fig. 2 EQ-5D-5L results per domain. Euroqol 5 Dimensions 5 Levels questionnaire. Vertical axis = cumulative percentage; horizontal axis = follow-
up moment; b = baseline; m = 1 week after mediastinoscopy; w = weeks after start of treatment; m =months after start of treatment
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Fig. 3 EORTC QLQ-C30 quality of life scores. European Organisation for Research and Treatment of Cancer Quality of life Questionnaire C30.
Summary score from 0 to 100, where 100 represents best quality of life. Mean/median score with bars representing standard error/interquartile
range. Mediastinoscopy = 1 week after mediastinoscopy; w = weeks after start of treatment; m =months after start of treatment
Fig. 4 EORTC QLQ-LC13 lung cancer-specific quality of life scores. European Organisation for Research and Treatment of Cancer Quality of life
Questionnaire LC13. Score 0–100, 0 = the worst health you can imagine, 100 = the best health you can imagine. Mean/median score with bars
representing standard error/interquartile range. Mediastinoscopy = 1 week after mediastinoscopy; w = weeks after start of treatment; m =months
after start of treatment
Bousema et al. Trials          (2021) 22:168 Page 10 of 13
Research and Treatment of Cancer (EORTC) Quality
of life Questionnaire C30 (QLQ-C30). The scoring
profiles on the five domains of the EQ-5D-5L (mobil-
ity, self-care, activity, pain and anxiety) will be pre-
sented in stacked histograms per follow-up moment
(Fig. 2). Separately, the Euroqol visual analogue scale
representing the quality of life on a scale will be pre-
sented (0–100, 0 = the worst health you can imagine,
100 = the best health you can imagine). The EORTC
QLQ-C30 incorporates five functional scales (physical,
role, cognitive, emotional and social), three symptom
scales (fatigue, pain and nausea and vomiting), a glo-
bal health status and a number of general cancer
symptoms (dyspnoea, loss of appetite, insomnia, con-
stipation, diarrhoea and perceived financial impact of
the disease). The EORTC QLQ-C30 will provide a
summary score from 0 to 100, where 100 represents
best quality of life, which will be presented by using a
diagram presenting the mean or median score includ-
ing its standard error or interquartile range per
follow-up moment (Fig. 3). The lung cancer-specific
quality of life will be measured using the QLQ-LC13
questionnaire, which also provides a summary score
from 0 to 100, with 100 representing best quality of
life. The results will also be presented in a diagram
presenting the scores per follow-up moment (Fig. 4).
All quality of life questionnaires will be filled in by
the patients at baseline, 1 week after mediastinoscopy
(if performed) and after 2 and 4 weeks and 3, 6, 12
and 24 months after start of treatment. Data presenta-
tion will be done using figures separately for the
questionnaires per randomisation group on all follow-
up moments. Comparisons between treatment groups
over time will be done using generalised mixed mod-
elling for continuous measures or generalised estima-
tion equations for counts. Absolute values of the
quality of life questionnaire results will be reported as
tables in supplementary material.
Discussion
The MEDIASTrial will determine if confirmatory me-
diastinoscopy can be safely omitted after tumour
negative endosonography in invasive mediastinal nodal
staging of patients with resectable non-small cell lung
cancer. Registration of the study in the Netherlands
Trial Register (NL6344/NTR6528) before start of the
study, publication of the full study protocol and the
present statistical analysis plan before knowledge of
any results was done to enhance transparency of sci-
entific behaviour [5]. We expect the inclusion to be
complete in 2020 and we aim to publish the primary
outcome measure shortly after completion of the
inclusion.
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surgery; 95% CI: 95% confidence interval; EQ-5D-5L: Euroqol 5 Dimensions 5
Levels questionnaire; EORTC: European Organization for Research and
Treatment of Cancer; VAS: Visual analogue scale
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